A prospective open label clinical trial to evaluate the topical viral load reduction potential of ColloidalSilver (NanoAgCideTM) based hand sanitizer on SARS-CoV-2 infected subjects.

WeInnovate Biosolutions Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年10月17日

试验速览

暂无简介。

•1. Male or Female aged 18 to 80 years (both inclusive) of age tested SARS-CoV-2 positive within last
•8 days of study enrolment.
•2. Patients willing to sign written informed consent and are ready to comply to study procedure.
•3. SARS-CoV-2 positive asymptomatic or symptomatic patients who are under institutional
•quarantine.

•1. Patients requiring emergency treatment during enrolment.
•2. Patients on ventilator support.
•3. Pregnant or lactating woman.
•4. Subjects with history of sun burn on hands.
•5. Subjects with history of skin disorders or on medication for the same: Eczema, Urticaria, Psoriasis,
•Herpes, skin cancer, Lupus, Vitiligo, Fungal infection, Candidiasis.
•6. Subjects on treatment of any degree burns.
•7. Any kind of psychiatric disorder or a condition in the opinion of the investigator may hinder
•communication with the research team.
•8. Inability of the subject to cooperate or communicate with the research team.

发起方

WeInnovate Biosolutions Pvt Ltd